No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Pfizer lifted its full-year guidance on Tuesday, after healthy demand for its blood thinners and cancer drugs helped offset falling sales of Covid-19 medicines.
The US pharma giant posted third-quarter revenues of $16.6bn, largely unchanged on the same period a year earlier, weighed down by sliding sales of Covid vaccine Comirnaty and antiviral treatment Paxlovid. Once they were stripped out, however, revenues grew 7% operationally, with especially good performances from blood thinner Eliquis, bladder cancer treatment Padcev and the Vyndaqel family of medicines, which are used to treat transthyretin amyloidosis.
Adjusted profits were $0.87 per share, unchanged year-on-year but comfortably beating estimates for $0.73.
As a result, the company raised its full-year outlook. It now expects revenues to come in between $62bn and $64bn, with adjusted diluted earnings per share of between $2.95 and $3.05. It had previously guided for revenues between $60.5bn and $62.5bn, and EPS of between $2.80 and $3.00.
Albert Bourla, chief executive, called it a "strong" quarter, with "commercial momentum disciplined execution".
He continued: "Our obesity programme continued to advance and recent milestones in oncology, immunology and vaccines further demonstrate the potential of our pipeline. With a robust slate of expected catalysts ahead, I believe we're well positioned to deliver meaningful new medicines for patients and lasting value."
Shares in Pfizer nudged higher as trading got underway on Wall Street, putting on nearly 1%.
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.